Image

PTO/SB/17 (10-03)

Approved for use through 07/31/2006. OMB 0651-0032

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

		<u> </u>				
EE TRANSI	/ΙΤΤΔΙ	Complete if Known				
		Application Number	09/765,231			
for FY 20	<i>)</i> 04	Filing Date	January 18, 2001			
Effective 10/01/2003. Patent fees are subj	ect to annual revision.	First Named Inventor	Phippard			
Applicant claims small entity status.	See 37 CFR 1.27	Examiner Name	R. Schnizer			
		Art Unit	1635			
TOTAL AMOUNT OF PAYMENT	(\$) \$0.00	Attorney Docket No.	S03221			

METHOD OF PAYMENT (check all that apply)			FEE CALCULATION (continued)						
Check Credit card Money Other None			3. ADDITIONAL FEES						
Deposit Account:			Large Fee	ntity Fee	Smal Fee	LEntity Fee	•		
Deposit Account		10 1025		Code	(\$)	Code	(\$)	Fee Description	Fee Paid
Number		19-1025		1051	130	2051		Surcharge - late filing fee or oath Surcharge - late provisional filing fee or cover	
Deposit Account Name Pharmacia Corportion		1052	50	2052	25	sheet			
		1053	130	1053	130	Non - English specification			
The Director i	s authorized t	o: (check all t	that apply)	1812	2,520	1812	2,520	For filing a request for ex parte reexamination	
Charge fee(s) indicated below Credit any overpayments			1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action		
Charge any additonal fee(s) or any underpayment of fee(s)			1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner		
Charge fee(s) indicated below, except for the filing fee			1251	110	2251	55	action Extension for reply within first month		
to the above-identified deposit account.			1252	420	2252		Extension for reply within second month	=	
FEE CALCULATION			1253	950	2253		Extension for reply within third month		
BASIC FILING FEE Large Entity Small Entity				1,480	2254		Extension for reply within fourth month		
Fee Fe	e Fee Fee	шу Fee Descriptio	on		2,010	2255		Extension for reply within fifth month	
Code (\$)	1	I Miller Siling Son	Fee Paid	1401	330	2401	•	Notice of Appeal	
1001 770 1002 340		Utility filing fee Design filing fee		1402	330	2402	165	Filing a brief in support of an appeal	
1002 540			·	1403	290	2403	145	Request for oral hearing	
1004 770	1	J	ee	1451	1,510	1451	1,510	Petition to institute a public use proceeding	
1005 160	2005 80			1452	110	2452	55	Petition to revive - unavoidable	
SUBTOTAL (1) (\$)		1453	1,330	2453	665	Petition to revive - unintentional			
2. EXTRA CLAIM FEES FOR UTILITY AND				1501	1,330	2501	665	Utility issue fee (or reissue)	
Z. EXTRA	A CLAIM F		Fee from	1502	480	2502	240	Design issue fee	
Total Claims		Claims	below Fee Paid	1503	640	2503	320	Plant issue fee	
Independent	-20	** =	= 0.00	1460	130	1460	130	Petitions to the Commissioner	
Claims Multiple Depe			= 0.00	1807	50	1807	50	Processing fee under 37 CFR § 1.17(q)	
Large Entity	Small Ent			1806	180	1806	180	Submission of Information Disclosure Statement	
Fee Fee Code (\$		Fee Des	cription	8021	40	8021	40	Recording each patent assignment per property (times number of properties)	
1202 18 1201 86		Claims in exce		1809	770	2809	385	Filing a submission after final rejection (37 CFR § 1.129(a))	
1201 86		•	aims in excess of 3 dent claim, if not paid	1810	770	2810	385	For each additional invention to be examined (37 CFR § 1.129(b))	
1204 86	2204 43		ependent claims	1801	770	2801	385	Request for Continued Examination (RCE)	
over original patent		•	1802	900	1802	900	Request for expedited examination		
1205 18 2205 9 ** Reissue claims in excess of 20 and over original patent			of a design application Other fee (specify)						
l				(_p.co.,y	,			
SUBTOTAL (2) (\$) \$0.00								Fee Paid SUBTOTAL (3)	
**or number previously paid, if greater; For Reissues, see above				*Red	duced b	y Basic	Filing	Fee Paid SOBTOTAL (3) (\$)	
SURMITTED BY								Complete (if applicable)	

Registration No. Telephone 314-274-9094 Name (Print/Type Philip B. Polster, II 43,864 (Attorney/Agent) Date January 29, 2004 Signature

> WARNING: Information on this form may become public. Credit card information should not b included on this form. Provide credit card information and authorization on

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

AMENDMENT TRANSMITTAL LETTER (Large Entity) Applicant(s): D. Phippard, et al.							Docket No.	
Serial No. Filing Date Examiner 09/765,231 January 18, 2001 R. Schnizer					S03221/00 US Group Art Unit 1635			
Inventions Osteoarthritis Tissue Derived Nucleic Acids, Polypeptides, Vectors, and Cells								
TO THE COMMISSIONER FOR PATENTS: Transmitted herewith is an amendment in the above-identified application. The fee has been calculated and is transmitted as shown below.								
			CLAIMS A	S AM	ENDED			
	CLAIM	IS REMAINING	HIGHEST #		NUMBER EXTRA	RATE		ADDITIONAL
	†	RAMENDMENT	PREV. PAID FOR	٦	CLAIMS PRESENT			FEE
TOTAL CLAIMS	2!	5 -	59 =		 		3.00	\$0.00
INDEP. CLAIMS	4	<u> </u>	9 =		0	x \$86	5.00	\$0.00
Multiple Dependen	nt Claim	s (check if appl	licable)					\$0.00
<u> </u>		·	TOTAL ADDITIO	NAL F	FEE FOR THIS AME	ENDMEN	Γ	\$0.00
 □ No additional fee is required for amendment. □ Please charge Deposit Account No. in the amount of □ A check in the amount of to cover the filing fee is enclosed. ☑ The Director is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. ☑ Any additional filing fees required under 37 C.F.R. 1.16. ☑ Any patent application processing fees under 37 CFR 1.17. 								
Philip B. Polster, II Reg. No. 43,864 Certify that this document and fee is being deposited on 01/29/04 with the U.S. Postal Service as first class mail under 37 C. F. B. 1.8 and is addressed to the								

Customer No. 26648

Commissioner for Patents, P.O. Box 1450, Alexandria, VA

22313-1450.

Signature of Person Mailing Correspondence

Keianaa N. Hall

Typed or Printed Name of Person Mailing Correspondence

CERTIFICATE OF N		Docket No.						
Applicant(s): D. Phippar		S03221/00 US						
O. C.IN.	File Date			O A 4 1 1 - 2				
Serial No.	Filing Date	Examiner		Group Art Unit				
09/765,231	January 18, 2001 R. Schnizer			1635				
nvention: Osteoarthritis Tissue Derived Nucleic Acids, Polypeptides, Vectors, and Cells								
OIPE								
FEB 0 2 2004 TRANFAMANTE								
I hereby certify that this	s Reply to Notice of NonCompi	iant Amendment, Fee Transmi (Identify type of correspondence)	ittai, A	mendment I ransmittai				
is being deposited wi	ith the United States Postal So		an en	velope addressed to:				
Commissioner for Pale	ents, P.O. Box 1450, Alexandria,	VA 22313-1450 011	Jani	January 29, 2004 (Date)				
		Keianaa N		<u> </u>				
		(Typed or Printed Name of Person	: Mailing \	Corresponaence)				
		Keinso	110	el				
		(Signature of Person Mailin	ng Corres	spondence)				
	Note: Each naner must ha	ve its own certificate of mailing.						
Note: Each paper must have its own certificate of mailing.								

Appl. No. 09/765,231

Response Dated 29 January 2004

Reply to Notice of Non-Compliant Amendment dated 5 January 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

1

IN RE APPLICATION OF:

PHIPPARD et al. | GROUP ART UNIT: 1635

SERIAL NUMBER: 09/765,231 | EXAMINER: R. SCHNIZER

FILED: 18 JANUARY 2001 | DATE: 8 DECEMBER 2003

ATTNY DKT NO.:3221/00-US | CONFIRMATION NUMBER: 7382

TITLE: OSTEOARTHRITIS TISSUE DERIVED NUCLEIC ACIDS, POLYPEPTIDES, VECTORS, AND CELLS

I hereby certify that this correspondence is beingdeposited with the United States Postal Service as First Class Mail in an envelope addressed to: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313 on January 29, 2004

REPLY TO NOTICE OF NON-COMPLIANT AMENDMENT UNDER 37 C.F.R. § 1.121

I. INTRODUCTORY COMMENTS

Commissioner of Patents and Trademarks

Alexandria, VA 22313

Sir:

This paper is in response to the Notice of Non-Compliant Amendment under 37 CFR § 1.121, dated 5 January 2004, the Shortened Statutory Period for Response set to expire on 5 February 2004. The claims have been corrected, and an explanation is set forth in the initial paragraph of the Remarks section. The entire remarks section is then reproduced, for the Examiner's convenience. Please charge any appropriate fees to Deposit Account No. 19-1025.

Amendments to the claims are reflected in the listing of claims, which starts on page 2 of this paper.

Remarks start on page 6 of this paper.